Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 18/20 | 0.43 |
| ▸ | ABL2 | P42684 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15907158 | 0.81 | KIT (0.55) | ABL1DDR1DDR2KIT | |
| SCHEMBL15907159 | 0.76 | MEN1 (0.40) | ABL1DDR1LMNAKIT | |
| SCHEMBL15800809 | 0.76 | ABL1 (0.42) | ABL1DDR1LMNAKIT | |
| SCHEMBL15907246 | 0.72 | GAA (0.37) | DDR1DDR2LMNAKIT | |
| SCHEMBL18323648 | 0.72 | ABL1 (0.64) | ABL1ABL2KIT | |
| SCHEMBL15907307 | 0.70 | CSF1R (0.40) | ABL1DDR1DDR2LMNAKIT | |
| Vamotinib SCHEMBL15789568 | 0.70 | ABL1 (0.80) | ABL1ABL2DDR1DDR2KIT | |
| Vamotinib SCHEMBL29441255 | 0.70 | ABL1 (0.80) | ABL1ABL2DDR1DDR2KIT | |
| Vamotinib SCHEMBL19475244 | 0.69 | ABL1 (0.76) | ABL1ABL2DDR1DDR2KIT | |
| SCHEMBL15907264 | 0.68 | ABL1 (0.36) | ABL1DDR1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | ABL1 1/4885ABL2 2/4885DDR1 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.